newsfilter
← Latest News
GlobeNewswire·

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

  • NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) announced management participation in two upcoming investor conferences.
  • CEO Michael Davidson, M.D. and EVP Matthew Philippe will attend the Jefferies Global Healthcare Conference 2026 in New York on Wednesday, June 3, 2026, at 10:30 a.m. ET.
  • The same executives will attend the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach on Tuesday, June 9, 2026, at 2:40 p.m. ET.
  • Live webcasts & archived replays for both presentations will be available via the investor relations section at ir.newamsterdampharma.com.
  • NewAmsterdam is developing obicetrapib, an oral CETP inhibitor, as a once-daily LDL-C lowering therapy for patients at risk of CVD who need adjuncts to statin therapy.
  • Obicetrapib is being investigated in multiple phase 3 trials alone or as a fixed-dose combination with ezetimibe.